What Ibudol-A Kid Treats: Main Uses and Benefits

Ibudol-A Kid supports symptomatic relief for the pediatric population, applied in addressing symptoms related to physical discomfort during acute illness. This combination is considered relevant in contexts involving heightened systemic burden where short-term symptomatic assistance is needed.

Dual Management of Pain and Fever (Antipyretic & Analgesic Benefit)

The medicine is commonly used to help with groups of symptoms that may appear suddenly, particularly the co-occurrence of elevated body temperature (fever) and pain related to physical discomfort. It is applicable in conditions characterized by periods of heightened symptoms such as the common cold, flu, localized irritative states, teething pain, and post-immunization reactions.

By applying symptomatic management to these pronounced symptoms, the medication may assist with short-term symptom stabilization and may help with supportive relief when symptoms interfere with routine activities.

“This medicine is relevant in situations involving certain distressing symptoms, contributing to improved comfort during periods of heightened symptoms.”

Quick Fact

Regulatory References

1. NIH DailyMed overview for the combination of Acetaminophen and Ibuprofen

This section details the official population eligibility and non-eligibility rules for Ibudol-A Kid, based strictly on governmental regulatory prescribing information for its active components (Ibuprofen and Acetaminophen) and combination products.

Contraindicated Populations (Absolute Non-Eligibility)

Use is contraindicated and absolutely prohibited for patients with the following conditions or history:

• Known hypersensitivity to Acetaminophen, Ibuprofen, or any other Nonsteroidal Anti-Inflammatory Drug (NSAID), including aspirin.
• A history of allergic-type reactions (e.g., asthma, urticaria) after taking aspirin or other NSAIDs.
• In the setting of Coronary Artery Bypass Graft (CABG) surgery.
• Pre-existing severe hepatic impairment or severe active liver disease.

Age and Use Restrictions

Conditional Use and Physiological Status

Use requires conditional restriction or avoidance in specific populations:

• Pregnancy: Use of the NSAID component is generally prohibited at or after 30 weeks gestation due to the risk of fetal harm.
• Organ Function: Patients with underlying liver disease or risk of renal toxicity are subject to restricted use.
• Cardiovascular: Use is generally avoided in patients with severe heart failure unless benefits outweigh the risk, as per regulatory warning.

Interactions with other medicines and products

Ibudol-A Kid, as a fixed-dose combination of an NSAID (Ibuprofen) and Acetaminophen (Paracetamol), has a defined interaction profile based on authoritative regulatory documentation. The combination presents interaction risks related to the properties of each active ingredient.

Officially Documented Interaction Constraints:

Co-administration with other products containing acetaminophen or NSAIDs is strictly prohibited to avoid duplicate therapy and subsequent increased risk of serious adverse events. The Ibuprofen component is documented to interfere with the antiplatelet effect of low-dose aspirin, which mandates a specific time separation requirement between the doses, typically requiring the immediate-release aspirin to be administered at least 30 minutes after or 8 hours before the Ibuprofen. Separately, the regulatory documentation highlights that concurrent chronic consumption of three or more alcoholic drinks daily is associated with an increased risk of severe liver damage due to the acetaminophen component. Caution is also noted for the combination of NSAIDs, ACE-inhibitors/ARBs, and diuretics in specific populations, such as elderly patients or those with pre-existing renal impairment, due to increased renal risk.

Peripheral Enzyme Inhibition and Anti-Signal Generation

The Ibuprofen component operates as a non-selective, reversible inhibitor of Cyclooxygenase (COX) enzymes in peripheral tissues. This interaction blocks the conversion of arachidonic acid into prostaglandins, which are key mediators that modulate nociceptor sensitivity and local vascular responses. The resulting reduction in prostanoid synthesis limits the signaling of chemical mediators at the site of peripheral activity.

Central Pathway Modulation and Thermoregulation

The Acetaminophen component primarily influences the Central Nervous System (CNS). It inhibits central COX activity to reduce PGE2 synthesis in the hypothalamus, which facilitates the reversion of the body's elevated thermal set-point. Additionally, its metabolite modulates descending pain pathways, potentially via TRPV1 and CB1 receptors, contributing to the modulation of central nociceptive signaling.

Convergence and Mechanistic Synergy

The drug's action is defined by the complementary use of two distinct mechanisms: one component reduces the initiation of peripheral signals related to discomfort and temperature elevation, while the other modulates the central processing and dampening of nociceptive signals. This convergence engages dual mechanisms that support a comprehensive modulation of physiological responses associated with nociception and thermoregulation.

Administration and Dosing Protocol

Ibudol-A Kid, formulated as an oral suspension, is strictly administered via the oral route. The official instructions for this combination preparation establish a standardized, weight-based approach for the pediatric population. The required dose volume is calculated based on the child's body weight (in kilograms), which serves as the primary metric for determining the precise amount to be administered; age is used only when weight is unknown.

To ensure uniformity, the container must be shaken well before each use. Accurate dose delivery is secured through the use of the graduated syringe provided, which measures the dose in millilitres (mL). Labeled dose volumes typically fall between 5 mL and 12.5 mL, corresponding to the weight-based cohorts of children between 2 and 12 years of age.

Frequency and Constraints on Use

The official schedule dictates that administration should be on an as-needed basis. Doses must be spaced out by a minimum interval of 4 hours, and the total administered amount is constrained by a maximum limit of 4 doses in any 24-hour period. This administration regimen is strictly designated for short-term use only. Furthermore, the prescribing information requires specific consideration for dose adjustment in patients with existing conditions such as renal or hepatic impairment. This procedural structure ensures adherence to the standard for using this fixed-dose combination.

Research Evidence / Overview of Studies

Phase 3 Trials for Moderate-to-Severe Condition A

Research has explored whether treatment with Drug X is associated with outcomes for patients with moderate-to-severe Condition A.

• Two large-scale Phase 3 trials reported data regarding the primary outcome measure (Symptom Score) when evaluating Drug X. A change in Symptom Score findings was observed over 52 weeks.
• The trials investigated a range of doses and patient demographics, including those with certain pre-existing conditions.
• The most commonly reported adverse events included fatigue and headache.

Studies on Acute Symptoms

In another study, researchers examined the effect of Drug X injection on acute symptoms.

• This double-blind trial evaluated the use of Drug X compared with placebo in 250 individuals experiencing acute symptom flare-ups.
• Research also evaluated whether this medication was associated with a change in pain levels. The study provided data regarding patient-reported pain scales within the first 48 hours of administration.

Combination Therapy and Safety

Studies have also explored Drug X's potential use alongside other treatments and its safety profile.

• A randomized controlled trial (RCT) compared the combination of Drug X and Drug Z with Drug X alone. The study provided data on changes in the primary Symptom Score after 12 weeks of treatment.
• One study investigated a potential interaction between Drug X and Drug Y.
• Studies evaluated the safety profile, which included monitoring for side effects in different patient groups. Combined data provided information on the safety profile and whether changes in outcomes were reported.

Key Studies & References Assessment of Safety and Efficacy of Combination Therapy (Drug X and Drug Z) Compared to Monotherapy in Condition A: A Randomized Controlled Trial

Common questions about Ibudol-A Kid (FAQ)

Q: What is Ibudol-A Kid used for?

A: Ibudol-A Kid is used in children for the temporary relief of minor aches and pains due to the common cold, flu, sore throat, headaches, and toothaches. It is also indicated for the temporary reduction of fever. The specific uses are listed on the product label.

Q: How should I give Ibudol-A Kid to my child?

A: You should follow the dosage instructions provided on the package label or those given specifically by a healthcare professional. It is important to use the weight-based chart if available and to ensure the correct formulation is used. Never exceed the recommended dose.

Q: Can I give Ibudol-A Kid with other medicines?

A: Before administering Ibudol-A Kid with any other medication, including over-the-counter products or supplements, you must consult a doctor or pharmacist. Some products may contain similar active ingredients, which could lead to an accidental overdose.

Q: What are the possible side effects?

A: Like all medications, Ibudol-A Kid may be associated with side effects. Common reactions may include stomach upset or mild allergic reactions. Serious but rare side effects are also possible. If you observe any unusual or severe symptoms, seek immediate medical attention.

Storage Requirements

The official storage conditions for Ibudol-A Kid oral suspension mandate keeping the product at controlled room temperature, generally defined as not exceeding 30 C. The medicine must be kept in its original container with the cap tightly closed and must be protected from light. It is a mandatory requirement to keep the medicine out of the sight and reach of children to prevent accidental ingestion.

Stability and Disposal

The product must not be refrigerated or frozen. Once opened, the suspension has a limited in-use shelf-life and should typically be discarded 1 month after the bottle is first opened. Disposal of any unused or expired product must be executed in accordance with local requirements. If no local take-back program is available, the product should be mixed with an unappealing substance and sealed before discarding it in household trash.